Source - LSE Regulatory
RNS Number : 4286T
Beximco Pharmaceuticals Ltd
24 November 2021
 

24 November 2021

 

BEXIMCO PHARMACEUTICALS LTD.

 

Statement re: media comment  

 

Beximco Pharmaceuticals Limited ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, notes recent media reports in Bangladesh relating to Covid-19 vaccine supplies.

 

Reports suggest that the Serum Institute of India Private Limited (SII) will resume exports of Covid-19 vaccine doses into Bangladesh in December 2021. However, in line with the Company's announcement on 11 October 2021, Beximco Pharma is yet to receive any confirmation from SII in this regard. The Company remains in dialogue with the Government of Bangladesh and SII and a further announcement will be made as appropriate.

 

Reports also suggest that Beximco Pharma is building its own capacity to produce Covid-19 vaccines and that this capability could be operational within four-to-six weeks. While the Company can confirm that, as part of its ongoing mission to provide patients with affordable treatment options, it is in the process of establishing an in-house vaccine capability, this is still at an early stage. No decision has been made on whether this vaccine capability will focus on Covid-19 or other target disease areas. As above, any material developments will be announced as appropriate.

 

For further information please visit www.beximcopharma.com or enquire to

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, ext.20080

 

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, ext. 20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, ext.20030

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Vadim Alexandre / Abigail Wayne

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell / Sam Purewal

Tel: +44 (0)20 3727 1000

 

 

About Beximco Pharmaceuticals Limited

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 5,500 employees are driving the company towards achieving its aspiration to be among the most admired companies in the world.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SPCDZLBLFFLZFBF
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.